AstraZeneca invests $2bn in Summit Therapeutics to develop ivonescimab ADC combinations

AstraZeneca has agreed to invest $2 billion in Summit Therapeutics as part of an expanded oncology collaboration focused on combining Summit’s investigational bispecific antibody ivonescimab with AstraZeneca’s antibody-drug conjugates (ADCs).

The companies have signed a clinical collaboration to evaluate ivonescimab alongside sonesitatug vedotin (Sone-Ve), AstraZeneca’s Claudin-18.2-targeting ADC, in gastrointestinal cancers. They also intend to establish a broader global development programme combining ivonescimab with additional AstraZeneca cancer medicines, including other ADCs.

Under the initial clinical agreement, AstraZeneca and Summit will each contribute their respective medicines and share the costs of the combination trials. Both companies will retain development and commercial rights to their own medicines.

The arrangement gives AstraZeneca a strategic equity position in Summit while allowing the two companies to test whether their respective oncology technologies can be combined across multiple tumour types.

AstraZeneca takes 12% stake in Summit Therapeutics

The $2 billion investment will be made through newly issued preferred stock in Summit Therapeutics.

AstraZeneca will purchase approximately 109,000 preferred shares that are convertible into common stock. Following completion, the investment will give AstraZeneca rights equivalent to approximately 12% of Summit’s outstanding common stock, or about 10.6% on a fully diluted basis.

The investment is expected to close within one week. Any future conversion of the preferred shares into common stock will remain subject to customary regulatory clearances.

The structure differs from a conventional acquisition or an asset purchase. Summit retains development and commercial rights to ivonescimab, while AstraZeneca retains rights to its own medicines used in the collaboration.

Reuters reported that the agreement provides Summit with a significant capital injection while giving AstraZeneca access to ivonescimab and potential combination opportunities without acquiring Summit outright.

Ivonescimab and Sone-Ve to form initial combination

The first clinical programme will examine ivonescimab in combination with sonesitatug vedotin in gastrointestinal cancers.

Sone-Ve is an antibody-drug conjugate directed at Claudin-18.2 (CLDN18.2), a target associated particularly with gastrointestinal cancers. AstraZeneca describes the medicine as a potential first-in-class CLDN18.2 ADC containing a monomethyl auristatin E (MMAE) payload.

Ivonescimab takes a different approach. It is a bispecific antibody designed to target both PD-1 and VEGF in a single molecule, combining an immune-checkpoint mechanism with an anti-angiogenic mechanism.

The companies plan to initiate gastrointestinal cancer trials under the collaboration imminently.

The combination is intended to bring together different approaches to cancer treatment: targeted delivery of a cytotoxic payload through the ADC, immune modulation through PD-1 blockade and effects associated with VEGF inhibition.

The potential benefit of the combination remains a clinical question that will need to be established through trials.

Sone-Ve advances after positive Phase III results

The collaboration comes after AstraZeneca reported positive high-level results from the Phase III CLARITY-Gastric01 trial of Sone-Ve.

In July, AstraZeneca said the trial demonstrated a statistically significant and clinically meaningful improvement in overall survival among patients with second-line and later-line CLDN18.2-positive advanced gastric cancers compared with investigator’s choice of therapy. The study included patients with gastric cancer, gastroesophageal junction cancer or oesophageal adenocarcinoma whose tumours met the specified CLDN18.2 expression criteria.

AstraZeneca said the results could support expanding the population considered for Sone-Ve based on CLDN18.2 expression. The detailed results are scheduled for presentation at the European Society for Medical Oncology Congress 2026.

The positive Sone-Ve data provides the clinical-development backdrop for testing the ADC with ivonescimab.

Ivonescimab expands beyond lung cancer

Ivonescimab was developed by China’s Akeso and licensed to Summit for development and commercialisation in major territories outside China.

The medicine combines PD-1 blockade with VEGF inhibition in a single bispecific antibody. It is approved for certain non-small cell lung cancer indications in China, while Summit is developing it in multiple other cancer settings.

The company’s development programme includes Phase III studies in areas including non-small cell lung cancer, small cell lung cancer, biliary tract cancer, bladder cancer, triple-negative breast cancer, head and neck squamous cell carcinoma, colorectal cancer and pancreatic cancer.

The AstraZeneca collaboration potentially expands the role of ivonescimab beyond its existing development programme by pairing it with ADCs rather than evaluating it only as a standalone or chemotherapy-based treatment.

AstraZeneca plans broader ADC combinations

The initial Sone-Ve programme is only one component of the collaboration.

AstraZeneca and Summit have signed a memorandum of understanding with the intention of establishing a wider global development programme combining ivonescimab with AstraZeneca’s cancer medicines, including additional ADCs.

The companies have not established a binding development programme for every potential combination under the MOU. The initial clinical agreement covering ivonescimab and Sone-Ve is separate from the planned broader collaboration.

This gives AstraZeneca a potential route to test ivonescimab across its existing oncology portfolio while maintaining ownership of its individual medicines.

For Summit, the arrangement provides additional funding and access to AstraZeneca’s oncology development capabilities while preserving its commercial rights to ivonescimab.

Combination oncology becomes a strategic focus

The agreement reflects the growing interest in combining different cancer-treatment mechanisms rather than developing medicines solely as standalone therapies.

ADCs can deliver cytotoxic payloads to cells expressing a particular target, while immune-based therapies are designed to alter the interaction between tumours and the immune system. Bispecific antibodies can incorporate more than one biological target into a single molecule.

The commercial value of such combinations, however, depends on clinical evidence demonstrating that the combination provides meaningful benefits compared with existing treatment options.

For AstraZeneca, the agreement also provides a way to extend the potential reach of its ADC portfolio into additional treatment combinations. For Summit, the investment supplies capital for ivonescimab development while bringing a major oncology company into its development strategy.

The next milestones will be the initiation of the planned gastrointestinal cancer studies, additional data from ivonescimab’s Phase III programme and the further definition of the proposed broader collaboration between the two companies.

If the combination programmes generate positive clinical results, they could support further development of ivonescimab alongside AstraZeneca’s ADC portfolio. At this stage, however, the clinical benefit of the combinations remains to be established through prospective trials.

Market Signal: Large pharmaceutical companies are increasingly using strategic equity investments and clinical collaborations to access complementary oncology platforms without acquiring the underlying company or asset outright. In this case, AstraZeneca will retain rights to its medicines while Summit retains rights to ivonescimab.

Follow B2B Market Signal on social media for the latest business news, industry developments, market intelligence and analysis. Connect with us on LinkedIn and follow us on Instagram at @b2bmarketsignal for regular updates.